钆塞酸增强磁共振多回波Dixon序列T2*成像用于肝脏脂肪定量:能否用于肝功能评估
回顾性纳入242例3T肝脏MRI检查患者,按临床实验室表现分为肝功能正常组50例、轻度肝损伤组143例、重度肝损伤组30例,比较钆塞酸给药前及给药后10分钟T2*值及T2*下降率。T2*下降率在肝功能正常组与重度肝损伤组间(-0.2±4.9% vs 5.0±6.9%,p=0.002)及轻度肝损伤组与重度肝损伤组间(3.2±6.0% vs 5.0±6.9%,p=0.003)差异有统计学意义,但给药前后T2*值在各组间均无显著差异。作者认为该序列可能为重度肝损伤患者的肝功能恶化提供补充信息。
要点
- T2*下降率在重度肝损伤组为5.0±6.9%,高于肝功能正常组的-0.2±4.9%(p=0.002)。
- T2*下降率在重度肝损伤组为5.0±6.9%,高于轻度肝损伤组的3.2±6.0%(p=0.003)。
- 给药前后T2*值在肝功能正常、轻度及重度肝损伤组间均无显著差异(p=0.735和0.131)。
核心结论
- 在钆塞酸增强肝脏MRI方案中加入基于3D多回波Dixon梯度回波序列的T2*成像,可能为重度肝损伤患者的肝功能恶化提供补充信息。
研究设计与样本
- 回顾性研究,经IRB批准并豁免知情同意,共纳入242例在3T下行肝脏MRI(含给药前及给药后3D多回波Dixon快速梯度回波序列)的患者。
关键影像表现/征象
- T2*下降率在肝功能正常组为-0.2±4.9%,轻度肝损伤组为3.2±6.0%,重度肝损伤组为5.0±6.9%。
诊断标准与关键数值
- T2*下降率区分重度肝损伤组与肝功能正常组的ROC曲线下面积为0.74(95%CI:0.63-0.83)。
临床应用与阅片要点
- 原文结论指出,在钆塞酸增强肝脏MRI方案中加入3D多回波Dixon梯度回波序列T2*成像,可能为重度肝损伤患者的肝功能恶化提供补充信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the diagnostic value of T2* mapping using 3D multi-echo Dixon gradient echo acquisition on gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) as a tool to evaluate hepatic function.
MATERIALS AND METHODS: This retrospective study was approved by the IRB and the requirement of informed consent was waived. 242 patients who underwent liver MRIs, including 3D multi-echo Dixon fast gradient-recalled echo (GRE) sequence at 3T, before and after administration of gadoxetic acid, were included. Based on clinico-laboratory manifestation, the patients were classified as having normal liver function (NLF, n = 50), mild liver damage (MLD, n = 143), or severe liver damage (SLD, n = 30). The 3D multi-echo Dixon GRE sequence was obtained before, and 10 minutes after, gadoxetic acid administration. Pre- and post-contrast T2* values, as well as T2* reduction rates, were measured from T2* maps, and compared among the three groups.
RESULTS: There was a significant difference in T2* reduction rates between the NLF and SLD groups (-0.2 ± 4.9% vs. 5.0 ± 6.9%, p = 0.002), and between the MLD and SLD groups (3.2 ± 6.0% vs. 5.0 ± 6.9%, p = 0.003). However, there was no significant difference in both the pre- and post-contrast T2* values among different liver function groups (p = 0.735 and 0.131, respectively). A receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve for using T2* reduction rates to differentiate the SLD group from the NLF group was 0.74 (95% confidence interval: 0.63-0.83).
CONCLUSION: Incorporation of T2* mapping using 3D multi-echo Dixon GRE sequence in gadoxetic acid-enhanced liver MRI protocol may provide supplemental information for liver function deterioration in patients with SLD.
引用
- Yoo H, Lee JM, Yoon JH, et al. T2* Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment? Korean J Radiol. 2017. PMID: 28670163. doi:10.3348/kjr.2017.18.4.682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。